Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

AstraZeneca's mRNA deal with China's CanSino comes a year after the British pharma ended a cardiovascular and oncology collaboration with Moderna.

Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two that AstraZeneca dumped last year.. The Big ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.

AstraZeneca said on Wednesday a review of real-world data showed its COVID-19 vaccine provided equally effective protection against hospitalisation and death after two doses as with current mRNA ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.